Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two Part Study to Assess Comparative Bioavailability, Pharmacokinetics of a Single Dose of ACM-001.1, Two Single Doses of Pindolol (Part1) Followed by Evaluation of Steady State Pharmacokinetics, Pharmacodynamics of ACM-001.1 in HV (Part2)

Trial Profile

Two Part Study to Assess Comparative Bioavailability, Pharmacokinetics of a Single Dose of ACM-001.1, Two Single Doses of Pindolol (Part1) Followed by Evaluation of Steady State Pharmacokinetics, Pharmacodynamics of ACM-001.1 in HV (Part2)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Espindolol (Primary) ; Pindolol
  • Indications Cachexia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Actimed Therapeutics

Most Recent Events

  • 13 Dec 2024 According to an Actimed Therapeutics media release, results from this study have been published in The Journal of Cachexia, Sarcopenia and Muscle.
  • 13 Dec 2024 Results presented in the Actimed Therapeutics Media Release.
  • 04 Jan 2023 According to an Actimed Therapeutics media release, Status changed has been changed to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top